Novel Therapeutic Strategies to Combat HCC

Pages: 51 - 63
Published: Jan 1, 2014
Abstract
Since HCC is caused by the activation and aberrant expression of various proteins, development of any effective treatment requires targeting multiple signaling cascades simultaneously. Sorafenib, the first FDA approved drug in the United States for the treatment of HCC, was successful because it targets kinases of different signaling pathways at the same time. This approach has led to the development of a number of drugs, which target various...
Paper Details
Title
Novel Therapeutic Strategies to Combat HCC
Published Date
Jan 1, 2014
Journal
Pages
51 - 63
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.